Management of type 2 diabetes mellitus in the elderly: Special considerations

Drugs and Aging

Volumn 18, Issue 1, 2001, Pages 31-44

  Rosenstock, Julio ^a  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; STATIN; SULFONYLUREA DERIVATIVE; THIAZOLE DERIVATIVE; TROGLITAZONE;

AGE; AGED; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIET THERAPY; DISEASE SEVERITY; EXERCISE; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; LIFE EXPECTANCY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH PARESIS; TREATMENT PLANNING;

AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GERIATRICS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; SULFONYLUREA COMPOUNDS;

EID: 0035114670     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118010-00003     Document Type: Review

References (52)

1. Diabetes in the elderly: Diagnosis, pathogenesis, and therapy
2. Management of diabetes in the ederly: A clinical perspective
3. Diabetes mellitus in the ederly
4. Prevalence of diabetes, impared fasting glucose, and impaired glucose tolerance in U.S. adults: The third national health and nutrition examination survey 1998-1994
5. Economic consequences of diabetes mellitus in the U.S. in 1997
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33)
7. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
8. The 4S study: Implications for prescribing
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
10. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol and Recurrent Events (CARE) trial
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
12. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
13. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
14. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension
15. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure
16. Obesity
17. Position Statement. Standards of medical care for patients with diabetes mellitus
18. Position Statement. Nutrition recommendations and principles for people with diabetes mellitus
19. Oral antidiabetic agents: The emergence of ∝-glucosidase inhibitors
20. Sulfonylureas
21. Treatment of non-insulin-dependent diabetes mellitus and its complications: A state of the art review
22. Insulin therapy in type 2 diabetes mellitus
23. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas
24. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
25. Clinical profile of the novel sulphonylurea glimepiride
26. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents
27. Glimepiride, a new once-daily sulfonylurea: A double-blind placebo-controlled study of NIDDM patients
28. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study
29. Lower incidence of severe hypoglycemia in type 2 diabetic patients treated with glimepiride versus glibenclamide
30. Glimepiride: A review of its use in the management of type 2 diabetes mellitus
31. Metformin
32. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
33. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes
34. Thiazolidinediones: A new class of antidiabetic drugs
35. Pioglitazone reduces insulin resistance and improves beta-cell function in type 2 diabetes patients on long-term sulfonylurea therapy
36. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes
37. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes
38. The effect of combination therapy with pioglitazone and sulfonylurea on the lipid profile in patients with type 2 diabetes
39. Rosiglitazone is effective and well-tolerated in patients ≥65 years with type 2 diabetes
40. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus
41. Strategies to improve management of type 2 diabetes mellitus
42. An evaluation of new agents in the treatment of type 2 diabetes
43. New treatments for patients with type 2 diabetes mellitus
44. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients
45. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in noninsulin-dependent diabetes mellitus
46. Alpha-glucosidase inhibitors
47. Evening insulin strategy
48. Efficacy and safety of HOE901 (insulin glargine) in subjects with type 2 DM: A 28-week randomized, NPH insulin-controlled trial
49. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe
50. Safety efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old
51. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone